Global Lupus Nephritis Market: Industry Analysis & Outlook (2021-2030)
Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease where the immune system turns against the body, affecting vital organs. While the primary cause of the disease is unknown, it is expected that factors such as viruses, infections, pollutants, and toxic chemicals, along with family history plays a role in causing the disease. The disease is more common in women compared to men. Kidney damage from lupus erythematosus can vary from mild to severe. In lupus nephritis, glomeruli or the filtering units are damaged. As a result, waste from the blood does not get filtered. Lupus nephritis happens when lupus involves the kidneys. When the kidneys are inflamed, they cannot function normally and can leak protein. If not controlled, lupus nephritis can lead to kidney failure.
The treatment for Lupus Nephritis is based upon on its type, which is determined by the biopsy. Since, symptoms and severity vary from person to person, treatments are individually tailored to meet a person's particular circumstances.
The global Lupus Nephritis market is set to experience favourable growth driven by factors such as increasing African-American population, rising health care expenditure and accelerating economic growth. The major trends observed in the market are new drugs under pipeline for Lupus Nephritis, increasing research grants with rising public awareness about the disease. However, the growth of this budding market will be hindered by stringent regulations, associated risk and high cost.
The report “Global Lupus Nephritis Market: Industry Analysis & Outlook (2021-2030)” analyses the development of this market, with focus on the U.S, Europe and Japan markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The five major players: Aurinia Pharmaceuticals Inc., Roche Holding AG, Bristol-Myers Squibb, GlaxoSmithKline Plc. and AstraZeneca are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global Lupus Nephritis market along with the study of the regional markets.
The treatment for Lupus Nephritis is based upon on its type, which is determined by the biopsy. Since, symptoms and severity vary from person to person, treatments are individually tailored to meet a person's particular circumstances.
The global Lupus Nephritis market is set to experience favourable growth driven by factors such as increasing African-American population, rising health care expenditure and accelerating economic growth. The major trends observed in the market are new drugs under pipeline for Lupus Nephritis, increasing research grants with rising public awareness about the disease. However, the growth of this budding market will be hindered by stringent regulations, associated risk and high cost.
The report “Global Lupus Nephritis Market: Industry Analysis & Outlook (2021-2030)” analyses the development of this market, with focus on the U.S, Europe and Japan markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The five major players: Aurinia Pharmaceuticals Inc., Roche Holding AG, Bristol-Myers Squibb, GlaxoSmithKline Plc. and AstraZeneca are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global Lupus Nephritis market along with the study of the regional markets.
1. OVERVIEW
1.1 Introduction
1.2 Symptoms
1.3 Classification
1.4 Treatment
2. GLOBAL MARKET ANALYSIS
2.1 Global Lupus Nephritis Patient Population Forecast
2.2 Global Lupus Nephritis Market Forecast by Value
2.3 Global Lupus Nephritis Market by Region
3. REGIONAL MARKET ANALYSIS
3.1 The U.S.
3.1.1 The U.S. SLE Patient Population Forecast
3.1.2 The U.S. Lupus Nephritis Patient Population Forecast
3.1.3 The U.S. Lupus Nephritis Market Forecast by Value
3.2 Europe
3.2.1 Europe Lupus Nephritis Patient Population Forecast
3.2.2 Europe Lupus Nephritis Market Forecast by Value
3.3 Japan
3.3.1 Japan Lupus Nephritis Patient Population Forecast
3.3.2 Japan Lupus Nephritis Market Forecast by Value
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rise in African-American Population
4.1.2 Accelerating Economic Growth
4.1.3 Rising Health Care Expenditure
4.1.4 Increasing Prevalence of Lupus Nephritis
4.2 Key Trends & Development
4.2.1 Drugs under Pipeline for Lupus Nephritis
4.2.2 Increasing Research Grants
4.2.3 Rising Public Awareness
4.3 Challenges
4.3.1 Stringent Regulations
4.3.2 Associated Risk
4.3.3 High Costs
5. COMPETITION
5.1 Global Market
5.1.1 Global Lupus Nephritis Market- Revenue Comparison of Key Companies
5.1.2 Global Lupus Nephritis Market- Market Cap Comparison of Key Companies
6. COMPANY PROFILES
6.1 Aurinia Pharmaceuticals Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Roche Holding AG
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Bristol-Myers Squibb
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 GlaxoSmithKline Plc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
6.5 AstraZeneca
6.5.1 Business Overview
6.5.2 Financial Overview
6.5.3 Business Strategies
1.1 Introduction
1.2 Symptoms
1.3 Classification
1.4 Treatment
2. GLOBAL MARKET ANALYSIS
2.1 Global Lupus Nephritis Patient Population Forecast
2.2 Global Lupus Nephritis Market Forecast by Value
2.3 Global Lupus Nephritis Market by Region
3. REGIONAL MARKET ANALYSIS
3.1 The U.S.
3.1.1 The U.S. SLE Patient Population Forecast
3.1.2 The U.S. Lupus Nephritis Patient Population Forecast
3.1.3 The U.S. Lupus Nephritis Market Forecast by Value
3.2 Europe
3.2.1 Europe Lupus Nephritis Patient Population Forecast
3.2.2 Europe Lupus Nephritis Market Forecast by Value
3.3 Japan
3.3.1 Japan Lupus Nephritis Patient Population Forecast
3.3.2 Japan Lupus Nephritis Market Forecast by Value
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rise in African-American Population
4.1.2 Accelerating Economic Growth
4.1.3 Rising Health Care Expenditure
4.1.4 Increasing Prevalence of Lupus Nephritis
4.2 Key Trends & Development
4.2.1 Drugs under Pipeline for Lupus Nephritis
4.2.2 Increasing Research Grants
4.2.3 Rising Public Awareness
4.3 Challenges
4.3.1 Stringent Regulations
4.3.2 Associated Risk
4.3.3 High Costs
5. COMPETITION
5.1 Global Market
5.1.1 Global Lupus Nephritis Market- Revenue Comparison of Key Companies
5.1.2 Global Lupus Nephritis Market- Market Cap Comparison of Key Companies
6. COMPANY PROFILES
6.1 Aurinia Pharmaceuticals Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Roche Holding AG
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Bristol-Myers Squibb
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 GlaxoSmithKline Plc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
6.5 AstraZeneca
6.5.1 Business Overview
6.5.2 Financial Overview
6.5.3 Business Strategies
LIST OF CHARTS
Systemic Lupus Erythematous (SLE) & Lupus Nephritis (LN) Overview
Symptoms of Lupus Nephritis
Global Lupus Nephritis Patient Population Forecast (2021-2030)
Global Lupus Nephritis Market Forecast by Value (2021-2030)
Global Lupus Nephritis Market by Region (2022/2030)
The U.S. SLE Patient Population Forecast (2021-2030)
The U.S. Lupus Nephritis Patient Population Forecast (2021-2030)
The U.S. Lupus Nephritis Market Forecast by Value (2021-2030)
Europe Lupus Nephritis Patient Population Forecast (2021-2030)
Europe Lupus Nephritis Market Forecast by Value (2022-2030)
Japan Lupus Nephritis Patient Population Forecast (2021-2030)
Japan Lupus Nephritis Market Forecast by Value (2022-2030)
African-American Population (2012-2016)
Global GDP Per Capita (2012-2016)
Global Health Care Expenditure Per Capita (2012-2016)
Annual Cost of Illness Per Patient by Disease (2016)
Global Lupus Nephritis-Revenue Comparison of Key Companies (2016)
Global Lupus Nephritis-Market Cap Comparison of Key Companies (2016)
Aurinia Pharmaceuticals Inc. Revenue by Geographic Region (2016)
Aurinia Pharmaceuticals Revenue and Net Loss (2012-2016)
Roche Holding AG Sales by Segments (2016)
Roche Holding AG Net Sales and Net Income (2012-2016)
Bristol-Myers Squibb Revenue by Segments (2016)
Bristol-Myers Squibb Revenue and Net Earnings (2016)
GlaxoSmithKline Plc. Revenue by Segments (2016)
GlaxoSmithKline Plc. Revenue and Net Profit (2012-2016)
AstraZeneca Revenue by Segments (2016)
AstraZeneca Revenue and Net Profit (2012-2016)
Systemic Lupus Erythematous (SLE) & Lupus Nephritis (LN) Overview
Symptoms of Lupus Nephritis
Global Lupus Nephritis Patient Population Forecast (2021-2030)
Global Lupus Nephritis Market Forecast by Value (2021-2030)
Global Lupus Nephritis Market by Region (2022/2030)
The U.S. SLE Patient Population Forecast (2021-2030)
The U.S. Lupus Nephritis Patient Population Forecast (2021-2030)
The U.S. Lupus Nephritis Market Forecast by Value (2021-2030)
Europe Lupus Nephritis Patient Population Forecast (2021-2030)
Europe Lupus Nephritis Market Forecast by Value (2022-2030)
Japan Lupus Nephritis Patient Population Forecast (2021-2030)
Japan Lupus Nephritis Market Forecast by Value (2022-2030)
African-American Population (2012-2016)
Global GDP Per Capita (2012-2016)
Global Health Care Expenditure Per Capita (2012-2016)
Annual Cost of Illness Per Patient by Disease (2016)
Global Lupus Nephritis-Revenue Comparison of Key Companies (2016)
Global Lupus Nephritis-Market Cap Comparison of Key Companies (2016)
Aurinia Pharmaceuticals Inc. Revenue by Geographic Region (2016)
Aurinia Pharmaceuticals Revenue and Net Loss (2012-2016)
Roche Holding AG Sales by Segments (2016)
Roche Holding AG Net Sales and Net Income (2012-2016)
Bristol-Myers Squibb Revenue by Segments (2016)
Bristol-Myers Squibb Revenue and Net Earnings (2016)
GlaxoSmithKline Plc. Revenue by Segments (2016)
GlaxoSmithKline Plc. Revenue and Net Profit (2012-2016)
AstraZeneca Revenue by Segments (2016)
AstraZeneca Revenue and Net Profit (2012-2016)
LIST OF TABLES
Classification of Lupus Nephritis (LN)
Voclosporin Commercial Opportunities
Voclosporin Potential Benefits
Development Stage of Voclosporin
Active Drug Development Programs for Lupus Nephritis
Bristol-Myers Squibb Acquisitions (2016)
Classification of Lupus Nephritis (LN)
Voclosporin Commercial Opportunities
Voclosporin Potential Benefits
Development Stage of Voclosporin
Active Drug Development Programs for Lupus Nephritis
Bristol-Myers Squibb Acquisitions (2016)
